That's a great question! Elahere (mirvetuximab soravtansine) is an antibody-drug conjugate (ADC) that targets folate receptor-alpha (FR-alpha) proteins, which are commonly found in ovarian cancer cells. It delivers chemotherapy directly to the tumor.
Typically, Elahere is used when carboplatin (Carbo) treatment is no longer Show Full Answer
That's a great question! Elahere (mirvetuximab soravtansine) is an antibody-drug conjugate (ADC) that targets folate receptor-alpha (FR-alpha) proteins, which are commonly found in ovarian cancer cells. It delivers chemotherapy directly to the tumor.
Typically, Elahere is used when carboplatin (Carbo) treatment is no longer working. So a combination trial of both together is less common, but research is always evolving.
Here's what's worth knowing:
- Combining treatments like ADCs with other therapies is an active area of research
- Clinical trials are testing new combinations to improve outcomes
- Eligibility often depends on prior treatments, tumor mutations, and overall health A MyOvarianCancerTeam member shared that researching clinical trials took around 20 hours, but breaking it into smaller sessions made it manageable. Visiting ClinicalTrials.gov and searching specific terms related to your situation is a great starting point.
It's always worth asking your oncologist directly about any trials you may qualify for — they may know of options not widely advertised!
May 1
Join
Your Privacy Choices
